TG Therapeutics Conference Call Summary Company Overview - **Company**: TG Therapeutics (NasdaqCM:TGTX) - **Focus**: B-cell mediated diseases, primarily multiple sclerosis (MS) - **Approved Drug**: Briumvi, an anti-CD20 monoclonal antibody for MS, launched in January 2023 - **Market Presence**: Available in 16 countries, with over 20,000 patients prescribed Briumvi to date [2][3] Core Market Insights - **Anti-CD20 Market**: Represents approximately $10 billion in sales, with Briumvi capturing about 20% of the total market share and one-third of the healthcare provider-administered segment [4][6] - **Growth Potential**: The anti-CD20 class holds a 50% market share in new prescriptions, indicating room for growth [4][5] Financial Performance - **2026 Revenue**: Total global revenues of $616 million, with U.S. net revenue of $594 million, reflecting a 90% year-over-year growth [7][9] - **Cumulative Revenue**: Exceeded $1 billion in cumulative net sales within less than three years of launch [6][7] - **Forecast for 2026**: Targeting $875 million to $900 million in global net revenue, primarily from U.S. sales [27][28] Product Development and Future Plans - **Upcoming Trials**: - Enhanced IV protocol aimed at consolidating dosing to simplify onboarding, with top-line data expected mid-2026 [18][19] - Development of a self-administered subcutaneous (subcu) version of Briumvi, with a pivotal study currently over 50% enrolled and a target launch in 2028 [20][21] - **Expansion Beyond MS**: Plans to explore additional indications for Briumvi, including myasthenia gravis (MG) and neuromyelitis optica (NMO) [25][26] Competitive Landscape - **Market Positioning**: Briumvi is positioned as the lowest-priced branded MS treatment, enhancing its appeal in a competitive market [12][13] - **Sales Force Strategy**: Plans to increase the sales force by 10%-20% to target high-opportunity healthcare providers [14][34] R&D and Pipeline - **Azer-cel**: An allogeneic off-the-shelf CD19 CAR-T product in development for progressive MS, with data expected in 2026 [25][44] - **Long-term Opportunities**: Patents extending into the mid-2040s, with ongoing evaluations for new indications and potential drug launches [31] Key Takeaways - **Market Dynamics**: Briumvi's growth trajectory is strong, with significant market share gains and a robust pipeline for future growth [30][31] - **Operational Efficiency**: The company maintains low operating expenses relative to revenue, indicating potential for profitability acceleration [31][29] - **Patient Engagement**: Emphasis on patient awareness campaigns to drive market share, recognizing the importance of shared decision-making in MS treatment [15][16] Conclusion - TG Therapeutics is well-positioned for continued growth in the MS market with Briumvi, supported by strategic product development and a focus on patient and healthcare provider engagement. The company anticipates significant revenue growth and operational efficiency in the coming years, with a strong pipeline of future products and indications.